| abstract |
Tumor cells often evade immune responses, eg, by reducing or eliminating MHC expression and/or IFN signaling, which enables uncontrolled growth. Here we demonstrate that antibody-based immunotherapy combined with IL2 administration is an effective treatment against such resistant tumors. In particular, the present disclosure relates to methods of treating a subject having a cancer that is at least partially resistant to an MHC-dependent T cell response, comprising administering to the subject: a. a polypeptide comprising or encoding IL2 or a functional variant thereof A polynucleotide comprising a polypeptide of IL2 or a functional variant thereof; and b. Antibody-based immunotherapy. |